Intensity Therapeutics Inc. is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. Intensity leverages its DfuseRx(SM) technology platform to create new, proprietary drug formulations, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity Therapeutics Inc. is based in WESTPORT, Conn.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-16.27M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.74 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -612.44% |
| Return on Assets (Trailing 12 Months) | -287.43% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.40 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.40 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.04 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.05 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.13 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.17 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.82 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 47.06M |
| Free Float | 39.01M |
| Market Capitalization | $14.68M |
| Average Volume (Last 20 Days) | 5.39M |
| Beta (Past 60 Months) | 3.25 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 17.10% |
| Percentage Held By Institutions (Latest 13F Reports) | 3.74% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |